Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA presiding officer Karen Midthun again rebuffs the company's request to convene experts other than the Oncologic Drugs Advisory Committee, but notes that new members are expected to join the panel before the June 28-29 hearing on withdrawing bevacizumab's accelerated approval.

You may also be interested in...



Makena Withdrawal Hearing: US FDA Drugs Center, Covis Tussle Over Panel Composition

Practicing obstetricians who are maternal fetal-medicine specialists should make up a ‘significant proportion’ of the advisory committee at the forthcoming hearing, Covis says; CDER calls for a more ‘balanced’ panel that includes expertise in biostatistics, neonatology and epidemiology.

Avastin On Trial: The Jurors (Updated)

Avastin On Trial: The Jurors (Updated)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel